Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation.
Saved in:
| Title: | Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation. |
|---|---|
| Authors: | Tolf, Andreas (AUTHOR), Fagius, Jan (AUTHOR), Carlson, Kristina (AUTHOR), Åkerfeldt, Torbjörn (AUTHOR), Granberg, Tobias (AUTHOR), Larsson, Elna‐Marie (AUTHOR), Burman, Joachim (AUTHOR) |
| Source: | Acta Neurologica Scandinavica. Nov2019, Vol. 140 Issue 5, p320-327. 8p. |
| Subjects: | Hematopoietic stem cell transplantation, Multiple sclerosis, Hematopoietic stem cells, Cerebrospinal fluid |
| Abstract: | Objectives: To determine whether treatment with autologous hematopoietic stem cell transplantation (HSCT) can induce sustained complete remission in patients with multiple sclerosis (MS). Material and methods: Case series of patients with relapsing‐remitting MS (n = 10) treated at a single center between 2004 and 2007 and followed up for 10 years. The patients were treated with a BEAM/ATG conditioning regimen (n = 9) or a cyclophosphamide/ATG conditioning regimen (n = 1) followed by infusion of unmanipulated autologous hematopoietic stem cells. The primary endpoint was sustained complete remission. Sustained complete remission was defined as "no evidence of disease activity‐4," sustained for a period of at least 5 years without any ongoing disease‐modifying treatment. Furthermore, MS was considered as "resolved" if intrathecal IgG production and cerebrospinal fluid neurofilament light levels were normalized as well. Results: Five out of 10 patients were in sustained complete remission at the end of the study. In three of them, MS was resolved. Conclusions: Our data demonstrate that sustained complete remission after autologous HSCT for MS is possible. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Objectives: To determine whether treatment with autologous hematopoietic stem cell transplantation (HSCT) can induce sustained complete remission in patients with multiple sclerosis (MS). Material and methods: Case series of patients with relapsing‐remitting MS (n = 10) treated at a single center between 2004 and 2007 and followed up for 10 years. The patients were treated with a BEAM/ATG conditioning regimen (n = 9) or a cyclophosphamide/ATG conditioning regimen (n = 1) followed by infusion of unmanipulated autologous hematopoietic stem cells. The primary endpoint was sustained complete remission. Sustained complete remission was defined as "no evidence of disease activity‐4," sustained for a period of at least 5 years without any ongoing disease‐modifying treatment. Furthermore, MS was considered as "resolved" if intrathecal IgG production and cerebrospinal fluid neurofilament light levels were normalized as well. Results: Five out of 10 patients were in sustained complete remission at the end of the study. In three of them, MS was resolved. Conclusions: Our data demonstrate that sustained complete remission after autologous HSCT for MS is possible. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00016314 |
| DOI: | 10.1111/ane.13147 |
